Angiotensin type 2 receptor activation limits kidney injury during the early phase and induces Treg cells during the late phase of renal ischemia
Riyasat Ali, Sanket Patel, Tahir Hussain
Abstract
The angiotensin II type 2 receptor agonist C21 has been known to have a renoprotective role in various kidney pathologies. C21 treatment (before renal ischemia) attenuated postischemic kidney injury, kidney dysfunction, and immune cell infiltration during the injury phase. Also, C21 treatment modulated the kidney microenvironment by enhancing anti-inflammatory responses mainly mediated by IL-10. During the repair phase, C21 treatment enhanced IL-10-secreting CD4 T cells and FoxP3-secreting regulatory T cells in Sprague-Dawley rats.
Topics & Concepts
KidneyIschemiaImmune systemAgonistAngiotensin IIFOXP3MedicineAcute kidney injuryRenal ischemiaReceptorRenin–angiotensin systemEndocrinologyImmunologyInternal medicineReperfusion injuryBlood pressureComplement system in diseasesRenin-Angiotensin System StudiesAcute Kidney Injury Research